Brightsurf Science News & Current Events

June 06, 2004
Estrogen boosts memory in men with prostate cancer
High doses of estrogen improve long-term memory and decrease feelings of confusion in men whose testosterone levels have been lowered to treat advanced prostate cancer, according to a study conducted by Oregon Health & Science University Cancer Institute scientists.

CP-675,206, a novel monoclonal antibody, enlists the immune system to fight advanced melanoma
Early testing of an experimental human monoclonal antibody showed a striking benefit in patients with advanced melanoma, say researchers at The University of Texas M.

Hebrew University researchers win Kaye prize for gastro sustained release drug delivery system
Researchers at the Hebrew University School of Pharmacy have developed a new technology, which they call Gastro-Retentive Dosage Form (GDRF), that

Treatment advances in NSCLC presented today at ASCO
A new study reports the survival benefits of Camptosar® (irinotecan hcl injection) and Cisplatin for first-line treatment of advanced non-small cell lung cancer.

Increasingly used prostate cancer treatment less effective for younger men with higher grade tumors
In one of the first studies examining the effectiveness of hormone deprivation as a primary therapy for localized prostate cancer, Oregon Health & Science University researchers found that younger men and those with higher grade tumors are more likely to experience disease progression during treatment.

Biologic drug offers long-term, disease-free future to patients with rare leukemia-without chemo
A biological agent - a drug that wraps vitamin A inside bubbles of fat - used without chemotherapy appears to offer as many as one-third of patients with a rare form of leukemia an opportunity for a long-term, disease-free future, say researchers at The University of Texas M.

Negative prostate biopsy doesn't always mean cancer-free
Biopsies detect prostate cancer in about one-fourth of men with abnormal screening tests.

Encouraging results for drug that steps up when Gleevec fails
A new pill that targets several molecules implicated in the growth of cancer has shown promise in combating gastrointestinal tumors that no longer respond to the targeted drug Gleevec, according to a study led by scientists at Dana-Farber Cancer Institute.

ACTOS(R) (pioglitazone HCl) shows sustained efficacy over two years in type 2 diabetes
Long-term studies using the oral antidiabetic drug ACTOS® (pioglitazone HCl) alone, and in combination with other oral antidiabetic medications, found that it provided sustained improvements in glycemic control, insulin sensitivity and key lipid parameters over a 104-week period.

Pioglitazone HCI shown to lower blood pressure in hypertensive patients with type 2 diabetes
Type 2 diabetes and hypertension are commonly associated conditions, both of which carry an increased risk of cardiovascular disease.

Glivec(R) should not be interrupted in patients with advanced GIST
The French Sarcoma Group today announced results of a multi-center, Phase III trial demonstrating that Glivec®(imatinib) interruption in patients with advanced GIST was associated with a high risk of re-progression within the following year.

Researchers identify biomarker to predict response of colon cancer patients to chemotherapy regimen
Researchers at Fox Chase Cancer Center have identified a biomarker that can predict how well individual colon cancer patients will respond to a common chemotherapy regimen.

Lower risk of heart disease and stroke in people with Type 2 diabetes taking atorvastatin
A daily dose of the cholesterol-lowering drug atorvastatin (Lipitor) can reduce the risk of a first major cardiovascular event (heart attack or stroke) by more than one third in people with Type 2 diabetes, according to the results of the CARDS study presented today at the American Diabetes Association's 64th Scientific Sessions in Orlando, USA.

Camptosar in combination with targeted therapies shows survival benefit
Combination of Camptosar® (irinotecan HCL injection) and AvastinTM (bevacizumab) shows survival benefit in first-line treatment of advanced colorectal cancer.

New study links common cholesterol-lowering drugs to reduced prostate cancer risk
Men who take even small amounts of common cholesterol-lowering drugs such as Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer, according to a new study by Oregon Health & Science University Cancer Institute researchers.

Multicenter melanoma vaccine study demonstrates promising results
Results from the largest multi-site study to date evaluating a peptide-derived therapeutic vaccine for melanoma were released today by the Eastern Cooperative Oncology Group (ECOG) at the 40th Annual Meeting of the American Society of Clinical Oncology (ASCO) in New Orleans.

U. Iowa muscular dystrophy discovery may lead to new treatment approaches
Expressing high levels of a sugar-adding protein known as LARGE in mice that lack the protein can prevent muscular dystrophy in these animals, according to studies by researchers at the University of Iowa Roy J. and Lucille A.

Researchers unveil new clinical treatment in the fight against gastrointestinal cancer
A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors (GIST).

Studies show ACTOS(R) (pioglitazone HCl) has positive effects on various components of dyslipidemia
Two clinical studies presented at the American Diabetes Association's (ADA) Scientific Sessions showed that ACTOS® (pioglitazone HCl) has favorable effects on dyslipidemia (low HDL-C levels, high triglycerides and high levels of small, dense LDL-C) and insulin resistance.

Smart statistics for cancer diagnosis
CSIRO statisticians have developed a new way to subtype paediatric Acute Lymphoblastic Leukaemia (ALL), the most common form of cancer in children under 12.

New study shows Xeloda after surgery significantly increases number of patients free of colon cancer
New data from the X-ACT trial (Xeloda in Adjuvant Colon Cancer Therapy), involving almost 2,000 patients, was presented today at the American Society of Clinical Oncology (ASCO), demonstrating that Xeloda (capecitabine), a targeted oral chemotherapy, should replace the current standard therapy known as the Mayo Clinic regimen (intravenous 5-FU/LV) due to its superior efficacy and safety.

Looking to nature for better sunscreens wins Kaye prize for Hebrew University graduate student
A doctoral student at the Hebrew University of Jerusalem School of Pharmacy has found that more effective sunscreens can be produced by isolating compounds from several species of ancient organisms.

New breast cancer drug shrinks tumors or slows growth in up to half of women
A new and experimental breast cancer drug called lapatinib inhibited tumor growth in nearly half of women who took it for eight weeks in a national Phase I clinical trial, according to results of a study being presented at the annual American Society of Clinical Oncology meeting in New Orleans.

Atorvastatin halves stroke risk in diabetes patients - UK researchers announce
Patients with Type 2 diabetes and a CV risk factor would benefit from a cholesterol-lowering medicine according to results from the first ever specifically designed UK primary prevention statin trial announced today at the American Diabetes Association (ADA).

Latest results from international islet transplant study confirm potential patient benefits
The Immune Tolerance Network today released updated results from its multicenter clinical trial of the Edmonton Protocol for islet transplantation.

Patients with early stage, HER-2 positive breast cancer
According to a study conducted at The University of Texas M.

Gene therapy tested to protect bone marrow during chemotherapy
Researchers report progress toward the goal of employing gene therapy to help protect the bone marrow cells of cancer patients undergoing chemotherapy. is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to